Not exact matches
The class action, filed in United States District Court, Southern District
of New York, and docketed under 18 - cv - 02213, is
on behalf of a class consisting
of investors who purchased or otherwise acquired BRF American Depositary Receipts («ADRs») between April 4, 2013 and March 2, 2018, both dates inclusive (the «Class Period»), seeking to recover damages caused by Defendants» violations
of the federal securities laws and to pursue remedies under Sections 10 (b) and 20 (a)
of the Securities Exchange Act
of 1934 (the «Exchange Act») and Rule 10b - 5 promulgated thereunder,
against the Company and certain
of its top officials.
The class action, filed in United States District Court, for the District
of Illinois, Eastern Division, is
on behalf of a class consisting
of investors who purchased or otherwise acquired Akorn's securities between March 1, 2017 through February 26, 2018, both dates inclusive (the «Class Period»), seeking to recover damages caused by defendants» violations
of the federal securities laws and to pursue remedies under Sections 10 (b) and 20 (a)
of the Securities Exchange Act
of 1934 and Rule 10b - 5 promulgated thereunder,
against the Company and certain
of its top officials.
The suit was commenced
against NIB by Standard Bank Offshore Trust Company, which was later substituted by Dominion Corporate Trustees Limited,
on behalf of investors, who had purchased promissory notes issued by Eland Ghana Limited and guaranteed by NIB
The Klamann Law Firm has successfully handled numerous securities fraud cases
on behalf of investors and others
against broker - dealer firms, investment advisors, accountants, and other investment professionals.
Mr. Girard currently serves
on the leadership team in the Target and Sony data breach actions; serves as lead counsel in derivative litigation
on behalf of Wal - Mart shareholders arising out
of alleged bribery in Mexico, lead counsel for commodities
investors in litigation arising out
of the collapse
of a commodities futures merchant, and lead counsel in a multi-district «pay for delay» antitrust proceeding
against major pharmaceutical companies.
Investors wishing to bring claims
against these parties are therefore faced with the choice
of either seeking to obtain some control over the master fund (possibly through the appointment
of a liquidator) so that it can pursue direct claims or bringing a derivative action
on behalf of the master fund.
I'm tempted to list some
of the huger mistakes that courts have made, ranging from the RIM saga [
of which the New Yorker has a great piece today] and the collapse
of the BCCI brought by Deloittes
on behalf of BCCI
investors against the Bank
of England, which collapsed after 12 years... [more]